ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 8.56
(2.27%)
CNY 8.56
(2.27%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 541.83 Million CNY | -6.27% |
| 2022 | 578.1 Million CNY | -10.81% |
| 2021 | 648.17 Million CNY | 10.49% |
| 2020 | 586.61 Million CNY | -31.35% |
| 2019 | 854.47 Million CNY | -1.64% |
| 2018 | 868.72 Million CNY | 33.82% |
| 2017 | 649.14 Million CNY | 31.49% |
| 2016 | 493.68 Million CNY | 5.12% |
| 2015 | 469.65 Million CNY | 4.79% |
| 2014 | 448.16 Million CNY | 33.62% |
| 2013 | 335.39 Million CNY | 54.15% |
| 2012 | 217.57 Million CNY | 49.8% |
| 2011 | 145.24 Million CNY | 0.38% |
| 2010 | 144.69 Million CNY | 43.61% |
| 2009 | 100.75 Million CNY | 29.48% |
| 2008 | 77.81 Million CNY | 0.0% |
| 2007 | 77.81 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 140.4 Million CNY | -1.44% |
| 2024 Q1 | 123.4 Million CNY | -20.53% |
| 2024 Q2 | 142.44 Million CNY | 15.43% |
| 2023 Q4 | 155.27 Million CNY | 7.59% |
| 2023 FY | 541.83 Million CNY | -6.27% |
| 2023 Q2 | 120.35 Million CNY | -1.26% |
| 2023 Q3 | 144.31 Million CNY | 19.91% |
| 2023 Q1 | 121.89 Million CNY | -10.17% |
| 2022 Q1 | 136.72 Million CNY | -0.28% |
| 2022 Q4 | 135.68 Million CNY | -14.94% |
| 2022 FY | 578.1 Million CNY | -10.81% |
| 2022 Q3 | 159.52 Million CNY | 9.14% |
| 2022 Q2 | 146.16 Million CNY | 6.91% |
| 2021 FY | 648.17 Million CNY | 10.49% |
| 2021 Q1 | 152.25 Million CNY | -0.68% |
| 2021 Q2 | 165 Million CNY | 8.38% |
| 2021 Q3 | 193.8 Million CNY | 17.45% |
| 2021 Q4 | 137.1 Million CNY | -29.26% |
| 2020 Q4 | 153.28 Million CNY | 5.66% |
| 2020 FY | 586.61 Million CNY | -31.35% |
| 2020 Q1 | 101.65 Million CNY | -47.58% |
| 2020 Q2 | 186.6 Million CNY | 83.57% |
| 2020 Q3 | 145.07 Million CNY | -22.26% |
| 2019 FY | 854.47 Million CNY | -1.64% |
| 2019 Q4 | 193.92 Million CNY | -18.33% |
| 2019 Q3 | 237.45 Million CNY | 1.04% |
| 2019 Q2 | 235 Million CNY | 24.94% |
| 2019 Q1 | 188.08 Million CNY | -22.98% |
| 2018 Q4 | 244.19 Million CNY | 14.46% |
| 2018 Q3 | 213.33 Million CNY | -0.14% |
| 2018 FY | 868.72 Million CNY | 33.82% |
| 2018 Q1 | 197.54 Million CNY | 0.21% |
| 2018 Q2 | 213.64 Million CNY | 8.15% |
| 2017 Q3 | 175.49 Million CNY | 10.98% |
| 2017 Q4 | 197.12 Million CNY | 12.33% |
| 2017 FY | 649.14 Million CNY | 31.49% |
| 2017 Q1 | 118.38 Million CNY | -17.95% |
| 2017 Q2 | 158.13 Million CNY | 33.58% |
| 2016 FY | 493.68 Million CNY | 5.12% |
| 2016 Q4 | 144.28 Million CNY | 18.07% |
| 2016 Q3 | 122.19 Million CNY | -8.02% |
| 2016 Q2 | 132.84 Million CNY | 40.78% |
| 2016 Q1 | 94.36 Million CNY | -36.62% |
| 2015 Q4 | 148.88 Million CNY | 31.16% |
| 2015 FY | 469.65 Million CNY | 4.79% |
| 2015 Q1 | 91.24 Million CNY | -32.05% |
| 2015 Q2 | 116.01 Million CNY | 27.14% |
| 2015 Q3 | 113.51 Million CNY | -2.16% |
| 2014 Q3 | 113.4 Million CNY | 1.43% |
| 2014 FY | 448.16 Million CNY | 33.62% |
| 2014 Q1 | 88.68 Million CNY | -29.9% |
| 2014 Q2 | 111.8 Million CNY | 26.07% |
| 2014 Q4 | 134.28 Million CNY | 18.41% |
| 2013 Q4 | 126.51 Million CNY | 77.11% |
| 2013 FY | 335.39 Million CNY | 54.15% |
| 2013 Q1 | 63.38 Million CNY | -4.44% |
| 2013 Q2 | 74.05 Million CNY | 16.83% |
| 2013 Q3 | 71.43 Million CNY | -3.54% |
| 2012 Q4 | 66.33 Million CNY | 9.31% |
| 2012 FY | 217.57 Million CNY | 49.8% |
| 2012 Q2 | 59.49 Million CNY | 91.49% |
| 2012 Q3 | 60.68 Million CNY | 2.0% |
| 2012 Q1 | 31.06 Million CNY | 13.66% |
| 2011 Q2 | 44.66 Million CNY | 27.48% |
| 2011 Q1 | 35.03 Million CNY | -22.86% |
| 2011 FY | 145.24 Million CNY | 0.38% |
| 2011 Q4 | 27.33 Million CNY | -28.45% |
| 2011 Q3 | 38.2 Million CNY | -14.46% |
| 2010 Q4 | 45.42 Million CNY | 39.04% |
| 2010 Q3 | 32.66 Million CNY | 0.0% |
| 2010 FY | 144.69 Million CNY | 43.61% |
| 2009 FY | 100.75 Million CNY | 29.48% |
| 2008 FY | 77.81 Million CNY | 0.0% |
| 2007 FY | 77.81 Million CNY | 0.0% |